Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Announces Publication of Hemopurifie Preclinical Data

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Announces Publication of Hemopurifie Preclinical Data

 

Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

 

Results Support the Further Investigation of the Hemopurifier in Long COVID

 

 

 

December 2, 2025  – (Investorideas.com Newswire) Reports Breaking Medical Tech Stock news -  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publicationof a pre-clinical study entitled “Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin” in the pre-print online archive bioRxiv. This paper has simultaneously been submitted for consideration to a peer-reviewed journal.  

https://www.biorxiv.org/cgi/content/short/2025.11.21.689519v1

 

Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain, and cognitive difficulties such as “brain fog” - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.

 

 

Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID.  EVs have been found to contain viral particles and other cargo including microRNA which are tiny molecules that regulate the amount of proteins made and have been associated with abnormal blood clotting and inflammation.

 

Aethlon Medical’s Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.

 

The Hemopurifier has previously been shown to remove EVs and decrease microRNAs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had recovered from COVID-19. Large (100−500 nm) and small (40−200 nm) EVs were isolated from plasma samples to determine ability to bind to GNA (mannose positive) or be removed by the GNA affinity resin, respectively. Plasma of those with Long COVID contained elevated levels of both large and small EVs.  Mannose-positive large EVs were significantly increased in Long COVID patient samples comparison to recovered controls. Removal of small EVs by the GNA affinity resin correlated with mannose positive large EVs indicating the same glycan target for removal by the Hemopurifier was present in both populations.  NanoString analyses identified seven EV associated miRNAs significantly depleted by GNA affinity resin treatment of plasma. The use of Pathway activity interference software indicated that removal of these microRNAs may be associated with downregulation of inflammatory pathways, including JAK-STAT, and upregulation of tissue repair pathways.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2025/12021-aethlon-medical-aemd-hemopurifier-long-covid-preclinical-data-2025.asp

“The data from this ex vivo study is exciting because it demonstrated for the first time that the GNA affinity resin in our device removes extracellular vesicles in Long COVID patient samples and removes microRNAs associated with the JAK-STAT pathway which is a therapeutic target in current Long COVID clinical trials. We plan to further this work by examining if removal of EVs decreases SARSs -CoV-2 viral particles as viral persistence is thought to be an additional important pathogenic mechanism in Long COVD” said Steven P. LaRosa, MD, Chief Medical Officer at Aethlon Medical and senior author on the paper.  “While Oncology is our lead clinical indication, this pre-clinical provides additional evidence that EV removal is a target beyond cancer.  We see the potential of the Hemopurifier as “a pipeline within a single device” “said James Frakes, Chief Executive Officer at Aethlon.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company’s ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the manuscript described in this release being under review and may be rejected for publication, require substantial revision, or be interpreted differently by the scientific community; the Company’s ability to achieve and realize the anticipated benefits from potential milestones; the Company’s ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company’s ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company’s ability to manage and successfully complete its clinical trials, if initiated; the Company’s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. The preclinical findings described herein are preliminary in nature, have not been peer-reviewed, and may not be replicated in subsequent studies or clinical trials.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com   
917-513-5303

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

 

 

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

 

Actinium's (NYSE American: ATNM) High-Stakes Sprint: Betting Big on the Explosive Global Cancer Radiotherapy Boom; @ActiniumPharma

 

Actinium's (NYSE American: ATNM) High-Stakes Sprint: Betting Big on the Explosive Global Cancer Radiotherapy Boom; @ActiniumPharma

 

Stocks Mentioned: (NYSE American: $ATNM), (NYSE: $NVS), (NYSE: $LLY)

 

November 17, 2025- Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at the radiotherapy cancer market, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve outcomes for patients with advanced cancers.  Actinium is deploying its technologies, capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies focused on solid tumors, hematology and conditioning for cellular therapies.

 

The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and investment.

 

Paid news dissemination on behalf of Actinium

Read this article, featuring ATNM in full at https://www.investorideas.com/news/2025/biotech/11171-actinium-atnm-cancer-radiotherapy-market-growth-biotech-stock-analysis.asp

 

The cancer radiotherapy market, particularly the radioligand therapy (RLT) segment, is expanding swiftly. Novartis (NYSE: NVS), a dominant player in this arena, is targeting RLT revenue by broadening its portfolio of approved treatments and advancing its development pipeline. According to multiple sources, Novartis CEO Vas Narasimhan has estimated that the market for radioligand therapy (RLT) could be valued at between $25 billion and $30 billion.

 

Also reported in a Briefglance.com recent article, “Novartis is bolstering its position in the rapidly expanding field of targeted cancer therapy with a new radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The investment underscores the growing demand for personalized cancer treatments and positions Novartis to capitalize on a market projected for significant growth over the next decade.”

 

Continued:

Novartis’s Pluvicto, approved for prostate cancer sales exceeded $1.39 billion in 2024 and expected to reach approximately $4.3 billion by 2030. “.

 

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reporting in its recent 10Q filing: “Recently prioritized as our lead program, ATNM-400, is a highly innovative, first-in-class, and pan-tumor Actinium-225 (“Ac-225”) alpha-emitter targeted radiotherapy candidate with preclinical data in prostate cancer, non-small cell lung cancer (“NSCLC”) and breast cancer.

“We believe ATNM-400 has the potential to address critical gaps across multiple treatment settings in each of these targeted indications and can therefore address large patient populations. Actimab-A is our most advanced clinical-stage product candidate, which utilizes an antibody linked to Ac-225 to target CD33, a cell surface protein that Actimab-A is designed to target, that is expressed ubiquitously in acute myeloid leukemia (“AML”) and myelodysplastic syndromes (“MDS”) and on myeloid derived suppressor cells (“MDSC”).”

 

“We are evaluating Actimab-A’s potential to synergize with immune checkpoint inhibitors (“ICIs”) such as programmed cell death 1 (“PD-1) inhibitors in solid tumors by depleting MDSC immune cells. Iomab-ACT is our next-generation targeted conditioning agent we are developing with the intent to improve patient access to, and outcomes with, cellular therapies such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease (“SCD”).”

 

Commenting on the market opportunity in their 10Q, Actinium notes,”With the approval of Novartis’ (NYSE: NVS) Pluvicto® for patients with mCRPC post-taxane therapy and post ARPI therapy and prior to taxane therapy, targeted-radiotherapy has become a prominent component of the metastatic prostate cancer treatment paradigm. Pluvicto® generated sales of approximately $1.4 billion in the first nine months of 2025. In June 2025, Novartis announced it expects to file an FDA submission in the second half of 2025 for Pluvicto® in metastatic hormone sensitive prostate cancer (“mHSPC”) that could add approximately 42,500 additional patients to the addressable market for Pluvicto®. With approximately one-third of patients not responding to PSMA-directed radiotherapy and that virtually all patients will progress on PSMA-directed radiotherapy within 12 months, we believe this demonstrates the high unmet need for a non-PSMA prostate cancer therapy such as ATNM-400.

 

Continued:

“In August 2025, we received a letter from Novartis Pharmaceuticals Corporation (the “Novartis Letter”) that is incorporated in this Form 10-Q as an exhibit. In that letter, Novartis strongly objected to statements that Actinium made comparing ATNM-400 and Pluvicto®. Given that ATNM-400 is in preclinical development and that we clearly indicated as such, we believe that the Novartis Letter is highly unusual. We believe the particular statements cited by Novartis were not misleading and were accurate depictions of our research findings that evaluated ATNM-400 versus 177Lu-PSMA-617, the active agent in Pluvicto® as well as 225Ac-PSMA-617, a targeted radiotherapy that is not yet approved but is being evaluated by multiple companies including Novartis. As we have reported, ATNM-400 demonstrated superior tumor control and improved overall survival in preclinical studies in prostate cancer bearing animals compared to 177Lu-PSMA-617. In addition, ATNM-400 demonstrated efficacy in prostate cancer tumors that developed resistance to 177Lu-PSMA-617. Therefore, we do not agree with any of the claims made in the Novartis Letter and do not believe Novartis has requisite legal authority or basis to challenge Actinium. Therefore, we have not responded to Novartis but reserve all rights. We believe patients with mCRPC have high unmet needs that are not addressed by current therapies including Pluvicto® and intend to continue to develop ATNM-400 with the goal of addressing these patient needs.

 

Continued:

“With the only approved targeted radiotherapy in prostate cancer moving up in the treatment paradigm with very few differentiated products in clinical development, we believe there is a significant potential market opportunity for ATNM-400. Currently, over 30 PSMA-targeted radiotherapies are in various stages of development, of which few offer a substantial efficacy advantage compared to Pluvicto®. Re-treatment with PSMA-targeting agents has not yet been supported substantially in controlled clinical trials and could be less effective than targeting a different antigen due to potential reduction of PSMA surface expression as well as increased tumor heterogeneity following initial PSMA-targeted therapy.

 

Continued:

“We have demonstrated that ATNM-400’s differentiated target is expressed and druggable following ARPI therapy and PSMA radiotherapy. We believe ATNM-400 can therefore target a significant subset of the mCRPC patient population with aggressive disease who progressed on second generation ARPIs or have had no response to or progressed on Lu-177 labelled PSMA-targeted therapy. As ATNM-400 does not target PSMA, xerostomia or dry mouth, which can be a significant quality of life issue for patients with metastatic prostate cancer receiving PSMA-targeted radiotherapies as PSMA is expressed on salivary glands, would not be expected. Additionally, the antigen targeted by ATNM-400 is implicated in a pathway leading to ARPI-resistance in mCRPC patients and expression increases post-ARPI treatment; therefore, along with the tumor suppressing ability of Ac-225, ATNM-400 displays a compelling mechanism for synergy with ARPIs. This mechanistic synergy is supported by the complete tumor regression in 40 percent of tumor bearing animals treated with the combination of ATNM-400 and the ARPI enzalutamide. As a result, we believe ATNM-400 has the potential to address critical gaps in prostate cancer treatment as a monotherapy or in combination or sequenced with other therapeutic modalities.”

 

SEC filing https://ir.actiniumpharma.com/all-sec-filings#document-3317-0001213900-25-110979

 

Looking at other companies in the market which are taking a different approach, in September, Lila Biologics an AI/ML-driven protein therapeutics biotech company announced a global licensing and multi-target research collaboration with Eli Lilly and Company ( NYSE: LLY) focused on the discovery, development, and commercialization of novel radioligand therapies (RLTs) for imaging and treatment of solid tumors. Lila also announced the launch of its two protein therapeutic platforms, driven by artificial intelligence (AI) and machine learning (ML), to combat cancer and non-oncology diseases. Lila’s targeted radiotherapy (TRT)/oncology platform for solid tumors and long-acting injectables (LAI) platform for non-oncology conditions are utilizing Lila’s proprietary AI/ML-powered protein design engine to create the foundation for new drug discovery and breakthrough treatments for patients.

 

From the news:

“We are on a mission to transform patient care by harnessing machine learning-powered protein design and advanced technologies to deliver life-changing therapies to patients,” said Jake Kraft, CEO and co-founder of Lila Biologics. “Lila’s core technology goes beyond ML-enabled design of high-affinity binders, and we’ve fine-tuned our engine to deliver precision targeted proteins with optimized drug-like properties that have the potential to unlock a new generation of treatments that dramatically improve patients’ quality of life and extend survival time.”

 

Earlier in the year, Eli Lilly and Company ( NYSE: LLY) entered into another collaboration in the sector.  AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.

 

From the news:

Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.

 

Continued:

AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.

 

Continued:

“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”

Research biotech and medical device/ tech stocks news and info at Investorideas.com

https://www.investorideas.com/BIS/

 

Disclaimer/Disclosure: This article featuring Actinium Pharmaceuticals, Inc. (ATNM) is paid for content. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

 

 

Medtech Stocks – How a company’s IP portfolio Creates Market Leaders

 

Medtech Stocks – How a company’s IP portfolio Creates Market Leaders

 

Stocks Mentioned: (Nasdaq: $AEMD), (NASDAQ: $IINN), (NASDAQ: $AMIX), (NYSE: $PHG)

 

 

September 4, 2025- Investorideas.com, a go-to investing platform covering biotech and medtech stocks releases an industry snapshot looking at innovation and the importance of IP in medtech,, featuring Aethlon Medical, Inc. (Nasdaq:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Medical Device Online reported in July, “The global medical device market is estimated to be currently about $680 billion and is projected to grow to over a trillion dollars within 10 years at a compound annual growth rate of 6%. As the medical device industry continues to expand, intellectual property (IP) considerations — especially those concerning patents — are critical for medical device innovators and manufacturers. For companies, developing IP is essential for securing funding, negotiating partnerships, and positioning themselves as leaders in the industry. For investors, a company’s IP portfolio signifies its ability to maintain market exclusivity and defend against competition.”

 

Aethlon Medical, Inc. (Nasdaq:AEMD) with its unique medical device, Hemopurifier®, is building an impressive list of patents issued and pending. It just announced that US Patent No. 12,409,260 ("the “260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the “453 Patent)” directed to the treatment of COVID-19-associated coagulopathy (“CAC”) was issued July 9, 2025.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news featuring AEMD in full at: https://www.investorideas.com/CO/AEMD/news/2025/09041medtech-stocks-ip-portfolio-market-leaders.asp

 

From the news:

The 260 Patent is intended to protect the use of the Hemopurifier® in the United States to treat patients that have a reduced COVID-19 viral load but exhibit Long COVID symptoms for more than 12 weeks post infection. The 260 Patent additionally protects the treatment of patients experiencing Long COVID symptoms by the removal of circulating COVID-19 spike protein.

 

The 453 Patent is intended to protect the use of the Hemopurifier® for the treatment of patients that lack circulating COVID-19 viral particles but exhibit COVID-19-associated CAC.

 

The 260 Patent was granted an additional 385 days of patent term due to patent term adjustment and will expire in 2042. The 453 Patent will expire in 2041.

 

"We believe securing these patents expands and strengthens our intellectual property portfolio in areas of significant unmet medical need,” said James Frakes, CEO and CFO of Aethlon. “While the Hemopurifier® remains in the research and development stage relating to Long COVID, these protections position us well as we continue advancing potential future applications. Our goal is to build a strong foundation of innovation that could one day translate into meaningful treatment options for patients."

 

The Aethlon Hemopurifier® is an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extra-corporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viral proteins. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses, fragments of viruses, and extracellular vesicles has been demonstrated in both in vitro studies and in human patients.

 

The Hemopurifier® holds a US Food and Drug Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

 

In addition to this patent news, Aethlon has the following patents issued and multiple patents pending in the US and Internationally:

 

International Patents issued

14 patents covering exosomes and microvesicular particle removal

• Patent protection extending to 2031 in Germany, France, Great Britain and Spain

• Patent protection extending to 2027 in Canada, Switzerland, Italy, Netherlands, Sweden, Hong Kong, Demark and Ireland

• 4 patents covering removal of Covid-19 viral particles and associated exosomes.

• Patent protection extending to 2041 in Unitary Patent member states, Switzerland, Great Britain and Spain

 

Issued Patents In United States:

• 4 patents issued covering extracorporeal removal of microvesicular particles, patent protection until 2029

 

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), a pioneer in innovative life-support and diagnostic technologies recently announced it received US Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company’s strategy to penetrate the $20 billion estimated market for advanced respiratory support. This innovation has 16 claims found to be novel.

 

From the news:

The patent provides further protection for the underlying core technology of Inspira’s ART500 system, which is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. This capability targets a large, underserved patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems, significantly expanding the potential market for Inspira's technology. This approval strengthens Inspira’s intellectual property portfolio and reinforces the Company’s technological leadership in the field of advanced extracorporeal life support.

 

Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of $20 billion. We are creating a new therapeutic category for conscious, spontaneously breathing patients. Protecting our intellectual property is a critical pillar of our growth strategy, and this patent approval provides us with a distinct competitive advantage. While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway needed to translate our technological leadership into long-term value for our shareholders, and a new standard of care for patients worldwide."

 

The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications. Inspira is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage.

 

In late August, Autonomix Medical, Inc. (NASDAQ:AMIX), a medical device company dedicated to advancing precision nerve-targeted treatments announced that European Patent Office (EPO) has granted Patent No. 3,697,298 (the ‘298 patent), titled, “Medical Device with Circuitry for Capturing and Processing Physiological Signals.” The newly issued ‘298 patent relates to use of its proprietary technology to collect and process sensing data for real-time physiological monitoring with broad application use that includes coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics and implants, and central nervous system monitoring for neurotherapy.

 

Earlier this year, Royal Philips (NYSE:PHG) announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing 594 Medtech patent applications. This achievement underscores the company's ongoing dedication to transforming healthcare delivery by integrating informatics and AI to improve workflows, enhance the quality of care, and lower costs of care per patient.

 

From the news:

AI-enabled cardiovascular ultrasound platform

 

The innovations by Philips, which can boast 134 years of innovation history with its research and development programs around the globe, improved the health and well-being of nearly 2 billion people in 2024, keeping it on track towards its target of 2.5 billion lives improved in 2030.

 

Roy Jakobs, CEO of Royal Philips said: "For more than 130 years, Philips has been at the forefront of innovations improving people’s lives. The 2024 European patent rankings show how we continue to innovate in the hospital and the home – helping to deliver better care for more people. To continue driving greater impact, we have shifted our innovation closer to customers. We want to help healthcare professionals improve patient care and empower people everywhere to take care of their health and well-being.”

As informatics and AI increasingly create value for healthcare, both at the hospital as well as at home, approximately half of the company’s R&D investments are focused on these technologies. 

 

 Some of the informatics and AI-powered innovations that Philips launched in 2024 include:

 

·        The new Azurion image-guided therapy system with advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients.

 

·        FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound system to advance cardiovascular imaging and increase automation and productivity, reinforcing Philips’ #1 global position in cardiovascular ultrasound.

 

·        The new Philips Spectral CT 7500 RT, enabling personalized radiation therapy planning to deliver better care to more cancer patients.

 

·        FDA approval for the LumiGuide Navigation Wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery.

 

In total, Philips contributed 1,231 European patent applications across various domains, the most of any Dutch company and continuing the company’s legacy as one of the top applicants since the EPO started publishing the rankings in 2004.

 

Based on market projections from leading analysts, the medical device market is set for significant expansion, fueled by technological advancements and growing healthcare needs.

 

Aethlon Medical, Inc. (Nasdaq:AEMD) is advancing its Hemopurifier® blood purification device globally with a growing patent portfolio to strengthen its long-term competitive advantage in the sector.

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/

 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com. AEMD is an annual featured showcase stock at Investorideas.com  This is not investment opinion. Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411